Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) announced the U.S. FDA lifted the partial clinical hold on its TakeAim Lymphoma Phase 1/2 study of emavusertib. Following the FDA's review, Curis is preparing to resume patient enrollment in Q3 2022. The hold was lifted after agreement on the strategy for managing rhabdomyolysis. Curis will provide a preliminary clinical data update in 2023. The TakeAim Lymphoma study explores emavusertib's effectiveness in treating hematologic malignancies, while the TakeAim Leukemia study remains on hold since April 2022.
Curis, Inc. (CRIS) reported promising clinical results for emavusertib and ibrutinib at ASCO 2022, showing tumor reduction in 8 of 9 evaluable patients, highlighting potential in overcoming ibrutinib resistance. The company appointed Diantha Duvall as CFO, bringing extensive industry experience. For Q2 2022, Curis recorded a net loss of $15.9 million ($0.17/share), a rise from a $10.8 million loss in Q2 2021. Revenue remained stable at $2.4 million. With a strong balance sheet of $107.2 million, Curis is funded into 2024. A conference call is scheduled for today to discuss these results.
Curis, Inc. (NASDAQ: CRIS) announced on July 22, 2022, that its Compensation Committee approved an inducement stock option grant for 540,000 shares to a new employee, effective on the employee's hire date of July 26, 2022. The exercise price matches the stock's closing price on that date. The options have a 10-year term and vest over four years. Curis is engaged in developing cancer therapeutics, including collaborations for innovative treatments. Notably, the FDA has placed a partial clinical hold on certain trials due to safety concerns.
Curis, Inc. (NASDAQ: CRIS) will release its Q2 2022 financial results on August 4, 2022, after the close of U.S. markets. A conference call will be held on the same day at 4:30 pm ET to discuss the results. Investors can dial in or access the call on Curis's website. The company focuses on developing innovative cancer therapeutics, with ongoing trials for its drug emavusertib and partnerships with organizations like Aurigene and Genentech. The FDA has placed a partial clinical hold on certain trials but allows current participants to continue treatment.
Curis, Inc. (NASDAQ: CRIS) announced the grant of 873,750 inducement stock options to 16 new employees, effective July 5, 2022. Each option has an exercise price equal to the closing stock price on that date and vests over four years. This move aims to attract talent and is part of their strategy in developing innovative cancer therapeutics, including ongoing clinical trials for the IRAK4 inhibitor, emavusertib. Curis faces a partial clinical hold on its TakeAim trials, impacting new patient enrollment.
Curis, Inc. (NASDAQ: CRIS) presented novel findings at the 2022 European Hematology Association Congress regarding the IRAK4 inhibitor, emavusertib. The data suggest that nuclear localization of IRAK4 in cancer cells, particularly in acute myeloid leukemia (AML), correlates with better treatment responses. Notably, one patient with primary CNS lymphoma achieved a complete response following emavusertib treatment after prior ibrutinib therapy. The company aims to develop a companion diagnostic for identifying patients most likely to benefit from emavusertib, which is currently undergoing trials for various hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) presented positive clinical data for emavusertib at the 2022 ASCO Annual Meeting. In the TakeAim Lymphoma study, 8 of 9 evaluable patients achieved tumor reduction, including 2 complete and 2 partial responses. Notably, complete response was observed in a patient with prior ibrutinib treatment, suggesting potential for overcoming ibrutinib resistance. In the TakeAim Leukemia trial, emavusertib showed promising single-agent activity in heavily pretreated AML and HR-MDS patients. The trials are currently under partial clinical hold by the FDA.
Curis, a biotechnology firm listed under NASDAQ: CRIS, will present a company overview at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 11:00 a.m. in New York. James Dentzer, President and CEO, will lead the presentation. A live webcast will be available on the Curis website, with a replay accessible for 90 days post-event. Curis focuses on cancer therapeutics, holding licenses for various innovative treatments, including emavusertib, currently in clinical trials, despite a partial hold by the FDA on certain trials. For more details, visit www.curis.com.
Curis (NASDAQ: CRIS) announces the upcoming presentations of multiple abstracts at the European Hematology Association 2022 Hybrid Congress from June 9-12, 2022, in Vienna. Key data from the TakeAim Lymphoma trial shows early anti-cancer activity with emavusertib combined with ibrutinib in heavily pretreated patients, including one complete response and two partial responses. Additionally, relevant insights from the TakeAim Leukemia study will also be shared. The company highlights the need for new treatment options for patients with resistant hematologic cancers.
Curis, a biotech firm, reported a net loss of $16.1 million for Q1 2022, compared to a loss of $9.9 million in Q1 2021. Revenues remained stable at $2.1 million. The company has a strong balance sheet with $120.7 million in cash, allowing operations to continue into 2024. Clinical updates include promising data for emavusertib, an IRAK4 inhibitor, though FDA has placed a partial hold on two studies. Initial safety data for CI-8993, an anti-VISTA antibody, were also discussed.